← BackBIOMERICA INC · In Vitro & In Vivo Diagnostic SubstancesBMRA
High riskNext report: Not enough history
The short versionA company still losing money with shrinking sales, with high risk. Institutions are adding.
Watch out for
- About 9 months of cash left at its current burn
- Losing money, losses are large next to sales
- Revenue down 16.2% from the year before
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 16% to their holdings in the quarter ending June 2026 (11 bought, 2 sold)
Facts from SEC filings, not a recommendation.
The business over time
Last 12 quarters, from SEC filings
Sales, Aug '26$1.3M-8.3% vs a year earlier
Nov '23Tap a barAug '26
Last 12 months: $4.3M, down 11% from the 12 months before. Over 5 years, sales shrank about 9.2% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.-79.1%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-84.8%
- MissProfitable every yearSteady profits, not one good year.0 of 10 years
- MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$3.4M
- MissShare count not growingNot diluting owners. Falling means buybacks.+3.0% in 3 years
- MissGross margin 40%+Pricing power: sells for well above what it costs to make.8.1%
- Revenue
- $4.5M
- -16.2% vs prior year
- 5-year growth
- -9.2%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 3.25x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Aug 31, 2026- Revenue
- $1.3M
- -8.3% YoY
- EPS
- -$0.37
- vs $0.00
- Op. margin
- -97.0%
- -16.0 pts
- Gross margin
- 8.1%
- -22.6 pts
- Free cash flow
- -$802K
- Share count
- +24.9%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 1.4
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+15.8%Institutions added 15.8% to their holdings. 11 bought, 2 sold. 4 quarters of net buying in a row.
Shares held by institutions125K
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-35.0%Cash runwayAt last year's cash burn
10 monthsDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
5MWhy high risk- Losing money, losses are large next to sales
- About 10 months of cash left at its current burn
- Revenue down 16.2% from the year before
- 3 offering filings in 6 months (may sell new shares)
Next reportNot enough history
- Results filedDec 16, 2021
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.